Relationship of Natriuretic Peptides with Left Atrial Structure and Function within 1 Month after Electrical Cardioversion in Patients with Persistent Atrial Fibrillation

Table 1

Patients’ baseline characteristics according to rhythm status after 1 month.

	Total (n= 48)	SR group (n = 26)	AF group (n= 22)	p value
Age, years	65.15±10.19	64.04±9.66	66.45±10.88	0.424
Sex, males	33 (67.3%)	18 (69.2%)	14 (63.6%)	0.480
AF history
<1 year	26 (53.1%)	15 (57.7%)	11 (50.0%)	0.433
1-3 years	8 (16.3%)	4 (15.4%)	4 (18.2%)
>3 years	14 (28.6%)	7 (26.9%)	7 (31.8%)
AF duration before ECV
<3 months	27 (55.1%)	17 (65.4%)	10 (45.5%)	0.178
3-6 months	13 (26.4%)	5 (19.2%)	8 (36.4%)	0.405
6-12 months	8 (16.3%)	4 (15.4%)	4 (18.2%)
Hypertension	42 (85.7%)	22 (84.6%)	20 (90.9%)	0.758
Diabetes	5 (10.2%)	5 (19.2%)	0
Echocardiographic parameters within the first 24 hours after SR restoration
Left ventricular ejection fraction, %	53.76±11.82	52.84±13.46	54.78±9.99	0.67
Left ventricular end diastolic diameter, mm	50.72±4.15	51.29±3.49	50.07±4.81	0.28
LA diameter, mm	48.66±4.26	48.21±4.09	49.17±4.52	0.61
LA volume, ml/m^2	51.85 (45.34-57.78)	49.94 (39.89-57.09)	52.10 (47.94-61.71)	0.19
LA reservoir function, %	24.16 (19.99-33.21)	24.79 (18.56-35.16)	24.12 (24.12-32.95)	0.85
LA conduit function, %	15.88±6.33	16.51±7.48	15.94±5.68	0.67
LA pump function, %	9.67 (6.97-14.88)	8.47 (6.27-15.02)	10.34 (7.63-13.74)	0.54
Medications
Propafenone	10 (20.4%)	2 (7.4%)	8 (36.4%)	0.06
Amiodarone	19 (38.8%)	16 (59.3%)	3 (13.6%)	0.003
β-blocker	45 (91.8%)	24 (88.9%)	21 (95.5%)	0.66
ACEI or ARB	37 (75.5%)	20 (74.1%)	17 (77.3%)	0.62
Statins	10 (20.4%)	6 (22.2%)	4 (18.2%)	0.53
Plasma levels of natriuretic peptides
NT-proBNP, ng/L	1763.50 (1030.25-2556.00)	2276.00 (918.00-3186.00)	1670.00 (1119.00-2280.25)	0.96
NT-proANP, ng/L	51181.00 (39243.00-82423.00)	55626.00 (41052.75-83724.75)	48133.00 (33972.50-73533.00)	0.31